| Literature DB >> 18780892 |
Elisa Ciraolo1, Manuela Iezzi, Romina Marone, Stefano Marengo, Claudia Curcio, Carlotta Costa, Ornella Azzolino, Cristiano Gonella, Cristina Rubinetto, Haiyan Wu, Walter Dastrù, Erica L Martin, Lorenzo Silengo, Fiorella Altruda, Emilia Turco, Letizia Lanzetti, Piero Musiani, Thomas Rückle, Christian Rommel, Jonathan M Backer, Guido Forni, Matthias P Wymann, Emilio Hirsch.
Abstract
The phosphoinositide 3-kinase (PI3K) pathway crucially controls metabolism and cell growth. Although different PI3K catalytic subunits are known to play distinct roles, the specific in vivo function of p110beta (the product of the PIK3CB gene) is not clear. Here, we show that mouse mutants expressing a catalytically inactive PIK3CB(K805R) mutant survived to adulthood but showed growth retardation and developed mild insulin resistance with age. Pharmacological and genetic analyses of p110beta function revealed that p110beta catalytic activity is required for PI3K signaling downstream of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors as well as to sustain long-term insulin signaling. In addition, PIK3CB(K805R) mice were protected in a model of ERBB2-driven tumor development. These findings indicate an unexpected role for p110beta catalytic activity in diabetes and cancer, opening potential avenues for therapeutic intervention.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18780892 PMCID: PMC2694958 DOI: 10.1126/scisignal.1161577
Source DB: PubMed Journal: Sci Signal ISSN: 1945-0877 Impact factor: 8.192